Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Stockoman1on Jun 29, 2019 2:43pm
62 Views
Post# 29876234

RE:RE:O'Neil

RE:RE:O'NeilThere is not likely another company with this huge percent market cap in cash like GUD. It is an abberation, and I am as tired of it as anyone. I only stay with it for now as Goodman has been transparent since he first laid out his strategy to build a pipeline of drugs in 5 years by financing micro companies ,  and has openly admitted it's failure since. 

Our friend Jacobsen however is not as open about his own financials, which raises a red flag. 
  Sure he has grown sales, but profits in decline?......Is he doing more deals to boost sales but not making money on them ?  He has had is kick at the" topple Goodman can" for now, and it didn't do much good. Repeating it over and over won't do it either. 
Bullboard Posts